Zacks Investment Research
16 Apr 2026, 15:26 UTC · 23w ago
Verdict
Headline leans bullish. We score GKOS +1.00 across two claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
2 claims · scored −1 bearish … +1 bullish
The U.S. Centers for Medicare and Medicaid Services (CMS) assigned a permanent HCPCS J-code (J2789) to Glaukos's Epioxa treatment.
More positive than 93% of claims this week
The new J-code for Epioxa becomes effective on July 1, 2026.
Continue reading
5 related stories
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 51% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The assignment of a permanent HCPCS J-code for Epioxa is expected to streamline reimbursement, improve market access, and support scalable growth.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
17h ago
+28.0%
Price agrees with the score
$154.88 vs $121.00 close before publication (Apr 15) · not market-adjusted
GKOS chart →
